Evidence map›Paper›PMID 25430940›Full record

ReviewAIDS care2015

Inclusion of trans women in pre-exposure prophylaxis trials: a review.

Daniel J Escudero, Thomas Kerr, Don Operario, Maria E Socías, Omar Sued, Brandon D L Marshall

Registry-linked trialAbstract readReview
In one paragraph

Review in AIDS care, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04050371 (I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones), which is not on this map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04050371 phase4completednot on this mapstarted 2017, after this paper: background citation

I-BrEATHe - Interactions Between Antiretrovirals And Transgender Hormones

TypeinterventionalSponsorUniversity of California, San FranciscoRan2017 to 2018Enrolled48ConditionsHIV Prevention, Transgender HealthArms200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Barriers and Facilitators to PrEP Initiation and Adherence Among Transgender and Gender Non-Binary Individuals in Southern California.AIDS education and prevention : official publication of the International Society for AIDS Education · 2020
    Article
  20. Characterizing PrEP Awareness and Interest Among Filipina Transgender Women.AIDS education and prevention : official publication of the International Society for AIDS Education · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel J Escuderoa Department of Epidemiology, School of Public Health , Brown University , Providence , RI , USA.
Thomas Kerr
Don Operario
Maria E Socías
Omar Sued
Brandon D L Marshall

Funding

Minority Populations Prevention Researcher TrainingR25HD045810 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NEILANDS, TORSTEN BRIAN · 2003 to 2018
$4.3M
Exploring transitions to injecting among young adult non-medical opioid usersR03DA037770 · NIDA · BROWN UNIVERSITY · PI MARSHALL, BRANDON DAVID LEWIS · 2014 to 2015
$335k
Estimating the impact of acute-stage HIV transmission among drug usersF31DA037808 · NIDA · BROWN UNIVERSITY · PI ESCUDERO, DANIEL · 2014 to 2015
$86k
NICHD NIH HHS R25 HD045810NIDA NIH HHS F31 DA037808NIDA NIH HHS F31-DA037808NIDA NIH HHS R03 DA037770
6 · The paper itself

Abstract

Trans women are at high risk of HIV infection. We conducted a review to determine the extent to which trans women were eligible for inclusion in and enrolled into pre-exposure prophylaxis (PrEP) efficacy trials. Out of seven trials analyzing PrEP efficacy, we found that trans women comprised only 1.2% of one trial and 0.2% of total trial enrollments. Although an additional PrEP trial to determine efficacy among trans women may not be warranted, further research is needed to determine the effectiveness of PrEP in this marginalized population, through observational and feasibility studies. These studies should focus on unique barriers that trans women may experience while obtaining access to PrEP, such as gender discrimination, transphobia, and violence.

Indexed as

Pre-Exposure ProphylaxisRandomized Controlled Trials as TopicTransgender PersonsAnti-HIV AgentsFemaleHIV InfectionsHumansMaleRiskVulnerable PopulationsAnti-HIV AgentsHIVmarginalized populationPrEPtransgendertrans women

Identifiers

PMID25430940
PMCPMC4336598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.